{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:07:49Z","timestamp":1790356069443,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["1200959"],"award-info":[{"award-number":["1200959"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03142-8","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:44:26Z","timestamp":1784799866000},"page":"2382-2393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-1326","authenticated-orcid":false,"given":"Chika","family":"Nitani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Karakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimikazu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"3142_CR1","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1200\/JCO.2005.05.571","volume":"23","author":"WB London","year":"2005","unstructured":"London WB, Castleberry RP, Matthay KK et al (2005) Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children\u2019s Oncology Group. J Clin Oncol 23:6459\u20136465","journal-title":"J Clin Oncol"},{"key":"3142_CR2","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324\u20131334","journal-title":"N Engl J Med"},{"key":"3142_CR3","doi-asserted-by":"crossref","unstructured":"Yu AL, Gilman AL, Ozkaynak MF et al. Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res 2021; 27: 2179\u201389.","DOI":"10.1158\/1078-0432.CCR-20-3909"},{"key":"3142_CR4","first-page":"1","volume":"13","author":"ME Keyel","year":"2019","unstructured":"Keyel ME, Reynolds CP (2019) Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics 13:1\u201312","journal-title":"Biologics"},{"key":"3142_CR5","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1097\/MPH.0000000000001684","volume":"43","author":"J Hara","year":"2021","unstructured":"Hara J, Nitani C, Kawamoto H et al (2021) A phase I\/IIa study of antidisialoganglioside antibody dinutuximab in Japanese patients with neuroblastoma. J Pediatr Hematol Oncol 43:e358\u2013e364","journal-title":"J Pediatr Hematol Oncol"},{"key":"3142_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1182\/blood.V82.3.931.931","volume":"82","author":"T Valerius","year":"1993","unstructured":"Valerius T, Repp R, de Wit TP et al (1993) Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931\u2013939","journal-title":"Blood"},{"key":"3142_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1046\/j.1365-2141.2002.03722.x","volume":"118","author":"B Stockmeyer","year":"2002","unstructured":"Stockmeyer B, Schiller M, Repp R et al (2002) Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody. Br J Haematol 118:959\u2013967","journal-title":"Br J Haematol"},{"key":"3142_CR8","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","volume":"182","author":"M Leidi","year":"1950","unstructured":"Leidi M, Gotti E, Bologna L et al (1950) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182:4415\u20134422","journal-title":"J Immunol"},{"key":"3142_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/scd.1.1995.4.415","volume":"4","author":"R Repp","year":"1995","unstructured":"Repp R, Valerius T, Wieland G et al (1995) G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2\/neu (MDX-210). J Hematother 4:415\u2013421","journal-title":"J Hematother"},{"key":"3142_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood.V86.3.1124.1124","volume":"86","author":"J Michon","year":"1995","unstructured":"Michon J, Moutel S, Barbet J et al (1995) In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside\/anti-Fc gamma RI bispecific antibody. Blood 86:1124\u20131130","journal-title":"Blood"},{"key":"3142_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2011.37.6236","volume":"30","author":"IY Cheung","year":"2012","unstructured":"Cheung IY, Hsu K, Cheung NK (2012) Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 30:426\u2013432","journal-title":"J Clin Oncol"},{"key":"3142_CR12","first-page":"281","volume":"5","author":"JA Hank","year":"1999","unstructured":"Hank JA, Surfus J, Gan J et al (1999) Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin Cancer Res 5:281\u2013289","journal-title":"Clin Cancer Res"},{"key":"3142_CR13","unstructured":"Jason Dearling SV, S. Ted Treves and Alan Packard. Radioimmunodetection of neuroblastoma: Expression of target antigen GD2 is changed by retinoic acid. Journal of Nuclear Medicine 2011:1675."},{"key":"3142_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long AH, Highfill SL, Cui Y et al (2016) Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res 4:869\u2013880","journal-title":"Cancer Immunol Res"},{"key":"3142_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-015-2955-9","volume":"77","author":"A Marachelian","year":"2016","unstructured":"Marachelian A, Desai A, Balis F et al (2016) Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol 77:405\u2013412","journal-title":"Cancer Chemother Pharmacol"},{"key":"3142_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100387","author":"N Siebert","year":"2018","unstructured":"Siebert N, Troschke-Meurer S, Marx M et al (2018) Impact of HACA on immunomodulation and treatment toxicity following ch14.18\/CHO long-term infusion with interleukin-2: results from a SIOPEN phase 2 trial. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers10100387","journal-title":"Cancers (Basel)"},{"key":"3142_CR17","doi-asserted-by":"crossref","unstructured":"Desai AV, Fox E, Smith LM et al. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer chemotherapy and pharmacology 2014; 74: 1047\u201355.","DOI":"10.1007\/s00280-014-2575-9"},{"key":"3142_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1080\/19420862.2015.1130196","volume":"8","author":"N Siebert","year":"2016","unstructured":"Siebert N, Eger C, Seidel D et al (2016) Pharmacokinetics and pharmacodynamics of ch14.18\/CHO in relapsed\/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs 8:604\u2013616","journal-title":"MAbs"},{"key":"3142_CR19","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1634\/theoncologist.2008-0166","volume":"13","author":"L de la Cruz-Merino","year":"2008","unstructured":"de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A et al (2008) Cancer and immune response: old and new evidence for future challenges. Oncologist 13:1246\u20131254","journal-title":"Oncologist"},{"key":"3142_CR20","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","volume":"19","author":"R Ladenstein","year":"2018","unstructured":"Ladenstein R, Potschger U, Valteau-Couanet D et al (2018) Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1617\u20131629","journal-title":"Lancet Oncol"},{"key":"3142_CR21","first-page":"1098","volume":"47","author":"K Mujoo","year":"1987","unstructured":"Mujoo K, Cheresh DA, Yang HM et al (1987) Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098\u20131104","journal-title":"Cancer Res"},{"key":"3142_CR22","first-page":"144","volume":"51","author":"E Barker","year":"1991","unstructured":"Barker E, Mueller BM, Handgretinger R et al (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51:144\u2013149","journal-title":"Cancer Res"},{"key":"3142_CR23","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1182\/blood.V82.11.3265.3265","volume":"82","author":"JM Kerst","year":"1993","unstructured":"Kerst JM, de Haas M, van der Schoot CE et al (1993) Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 82:3265\u20133272","journal-title":"Blood"},{"key":"3142_CR24","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1182\/blood.V73.7.1936.1936","volume":"73","author":"BH Kushner","year":"1989","unstructured":"Kushner BH, Cheung NK (1989) GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936\u20131941","journal-title":"Blood"},{"key":"3142_CR25","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2001.19.22.4189","volume":"19","author":"BH Kushner","year":"2001","unstructured":"Kushner BH, Kramer K, Cheung NK (2001) Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189\u20134194","journal-title":"J Clin Oncol"},{"key":"3142_CR26","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","volume":"30","author":"NK Cheung","year":"2012","unstructured":"Cheung NK, Cheung IY, Kushner BH et al (2012) Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 30:3264\u20133270","journal-title":"J Clin Oncol"},{"key":"3142_CR27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","volume":"45","author":"B Becher","year":"2016","unstructured":"Becher B, Tugues S, Greter M (2016) GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity 45:963\u2013973","journal-title":"Immunity"},{"key":"3142_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s002620050008","volume":"48","author":"RL Chen","year":"2000","unstructured":"Chen RL, Reynolds CP, Seeger RC (2000) Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 48:603\u2013612","journal-title":"Cancer Immunol Immunother"},{"key":"3142_CR29","doi-asserted-by":"crossref","unstructured":"Martinez Sanz P, van Rees DJ, van Zogchel LMJ et al. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment. J Immunother Cancer 2021; 9.","DOI":"10.1136\/jitc-2021-003983"},{"key":"3142_CR30","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1158\/0008-5472.CAN-12-4124","volume":"73","author":"G Kohanbash","year":"2013","unstructured":"Kohanbash G, McKaveney K, Sakaki M et al (2013) GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-\u03b1. Cancer Res 73:6413\u20136423","journal-title":"Cancer Res"},{"key":"3142_CR31","doi-asserted-by":"publisher","first-page":"9253","DOI":"10.1073\/pnas.85.23.9253","volume":"85","author":"S Dedhar","year":"1988","unstructured":"Dedhar S, Gaboury L, Galloway P et al (1988) Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci U S A 85:9253\u20139257","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3142_CR32","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1200\/JCO.2008.20.3075","volume":"27","author":"SJ O'Day","year":"2009","unstructured":"O\u2019Day SJ, Atkins MB, Boasberg P et al (2009) Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J Clin Oncol 27:6207\u20136212","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03142-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:06Z","timestamp":1790355006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03142-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3142"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03142-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author Nitani has an ongoing medical expert contract with Ohara Pharmaceutical Co., Ltd., which provided dinutuximab for this research, and received lecture and manuscript fees from Ohara Pharmaceutical Co., Ltd., for dinutuximab. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The study protocol was approved by the Institutional Review Board of each participating institution, and written informed consent was obtained from patients\u2019 guardians. This was an investigator-initiated trial funded by the Japan Agency for Medical Research and Development (AMED).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}